Table 5. Summary of limited long-term... | American Society of Hematology

Table 5.

Summary of limited long-term follow-up data from the TKI discontinuation trials⁴²

Trial	Treatment before discontinuation	No. of patients	Depth and duration of MR required for discontinuation	Trigger to resume TKI therapy	Median follow-up	Treatment-free remission rate
STIM1⁴⁹	Imatinib ± interferon	100	MR⁵ for at least 2 y	Loss of MR⁵	77 mo	38% at 60 mo
TWISTER⁵⁰	Imatinib ± interferon	40	MR^4.5 for at least 2 y	Loss of MR⁵	103 mo	45% at 8 y
HOVON⁵¹	Imatinib ± cytarabine	15	MR^4.5 for at least 2 y	Loss of MR^4.5	36 mo	33% at 24 mo
A-STIM⁵²	Imatinib ± interferon	80	MR⁵ for at least 2 y	Loss of MMR	31 mo	61% at 36 mo
ISAV⁵³	Imatinib (after failure of interferon or hydroxyurea)	108	CMR for at least 18 mo	Loss of MMR	36 mo	52% at 36 mo
KID⁵⁴	Imatinib ± interferon	90	MR^4.5 for at least 2 y	Loss of MMR	27 mo	59% at 24 mo
Stop 2G-TKI⁵⁵	Dasatinib/nilotinib (first or second line)	60	MR⁵ for at least 24 mo	Loss of MMR	47 mo	54% at 48 mo
DASFREE⁵⁶	Dasatinib (first or second line)	84	MR^4.5 for 12 mo	Loss of MMR	2 y	46% at 24 mo
ENESTFreedom⁶⁰	Nilotinib (first line)	190	MR^4.5 for 12 mo	Loss of MMR	96 wk	49% at 96 wk
ENESTop study⁶¹	Nilotinib (second line)	126	MR⁵ for at least 2 y	Loss of MMR	96 wk	53% at 96 wk
DADI⁵⁷	Dasatinib (first line)	68	MR^4.5 for at least 24 mo	Loss of MMR	23 mo	55% at 6 mo
DADI⁵⁸	Dasatinib (second line)	63	MR⁴ for at least 12 mo	Loss of MR⁴	44 mo	44% at 36 mo
EURO-SKI⁵⁹	Any TKI	758	MR⁴ for at least 1 y	Loss of MMR	27 mo	50% at 24 mo

Trial	Treatment before discontinuation	No. of patients	Depth and duration of MR required for discontinuation	Trigger to resume TKI therapy	Median follow-up	Treatment-free remission rate
STIM1⁴⁹	Imatinib ± interferon	100	MR⁵ for at least 2 y	Loss of MR⁵	77 mo	38% at 60 mo
TWISTER⁵⁰	Imatinib ± interferon	40	MR^4.5 for at least 2 y	Loss of MR⁵	103 mo	45% at 8 y
HOVON⁵¹	Imatinib ± cytarabine	15	MR^4.5 for at least 2 y	Loss of MR^4.5	36 mo	33% at 24 mo
A-STIM⁵²	Imatinib ± interferon	80	MR⁵ for at least 2 y	Loss of MMR	31 mo	61% at 36 mo
ISAV⁵³	Imatinib (after failure of interferon or hydroxyurea)	108	CMR for at least 18 mo	Loss of MMR	36 mo	52% at 36 mo
KID⁵⁴	Imatinib ± interferon	90	MR^4.5 for at least 2 y	Loss of MMR	27 mo	59% at 24 mo
Stop 2G-TKI⁵⁵	Dasatinib/nilotinib (first or second line)	60	MR⁵ for at least 24 mo	Loss of MMR	47 mo	54% at 48 mo
DASFREE⁵⁶	Dasatinib (first or second line)	84	MR^4.5 for 12 mo	Loss of MMR	2 y	46% at 24 mo
ENESTFreedom⁶⁰	Nilotinib (first line)	190	MR^4.5 for 12 mo	Loss of MMR	96 wk	49% at 96 wk
ENESTop study⁶¹	Nilotinib (second line)	126	MR⁵ for at least 2 y	Loss of MMR	96 wk	53% at 96 wk
DADI⁵⁷	Dasatinib (first line)	68	MR^4.5 for at least 24 mo	Loss of MMR	23 mo	55% at 6 mo
DADI⁵⁸	Dasatinib (second line)	63	MR⁴ for at least 12 mo	Loss of MR⁴	44 mo	44% at 36 mo
EURO-SKI⁵⁹	Any TKI	758	MR⁴ for at least 1 y	Loss of MMR	27 mo	50% at 24 mo